Stock listing
BX Swiss:8EM Editas Medicine, Inc. Aktie
Swiss listing (BX Swiss) of Editas Medicine, Inc. · home listing NASDAQ:EDIT
Follow Editas Medicine, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:EDIT
$1.64 USD -0.13 (-7.3%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:EDIT
- Day range
- $1.63 – $1.78 USDNov 20, 2026
- Volume
- 2.68M sharesNov 20, 2026
- Market cap
- $253.1M USDAt the close on Nov 20, 2026 · price × 154.3M shares outstanding
- 52-week range
- $1.63 – $3.94 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $7.14M USDMedian day 2.27M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:EDIT · Home | $1.64 USD | -0.13 (-7.3%) | 2,679,287 | $1.69 | $1.78 | $1.63 | $1.77 | Close on Nov 20, 2026 |
| LSE:0IFK | $1.678 USD | -0.102 (-5.7%) | 11,320 | $1.81 | $1.81 | $1.66 | $1.78 | Close on Nov 20, 2026 |
| Frankfurt:8EM | €1.545 EUR | -0.145 (-8.6%) | — | €1.545 | €1.545 | €1.545 | €1.69 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:EDIT · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.64 | -0.13 | -7.3% | $1.69 | $1.78 | $1.63 | 2,679,287 | |
| $1.77 | -0.055 | -3.0% | $1.86 | $1.945 | $1.76 | 1,989,397 | |
| $1.825 | -0.045 | -2.4% | $1.90 | $1.937 | $1.82 | 2,022,580 | |
| $1.87 | -0.30 | -13.8% | $2.10 | $2.12 | $1.86 | 2,105,770 | |
| $2.17 | +0.03 | +1.4% | $2.14 | $2.21 | $2.01 | 2,785,410 | |
| $2.14 | -0.24 | -10.1% | $2.32 | $2.32 | $2.12 | 3,881,551 | |
| $2.38 | -0.125 | -5.0% | $2.51 | $2.52 | $2.36 | 1,968,902 | |
| $2.505 | -0.245 | -8.9% | $2.70 | $2.75 | $2.48 | 1,589,910 | |
| $2.75 | +0.18 | +7.0% | $2.63 | $3.005 | $2.511 | 3,719,634 | |
| $2.57 | +0.02 | +0.8% | $2.55 | $2.63 | $2.475 | 1,715,866 | |
| $2.55 | -0.17 | -6.3% | $2.68 | $2.68 | $2.41 | 2,096,971 | |
| $2.72 | +0.12 | +4.6% | $2.70 | $2.79 | $2.61 | 2,368,229 | |
| $2.60 | +0.03 | +1.2% | $2.61 | $2.71 | $2.57 | 1,755,820 | |
| $2.57 | -0.10 | -3.7% | $2.71 | $2.778 | $2.55 | 1,236,276 | |
| $2.67 | -0.26 | -8.9% | $2.89 | $2.92 | $2.60 | 2,908,802 | |
| $2.93 | -0.02 | -0.7% | $2.945 | $2.98 | $2.86 | 3,224,947 | |
| $2.95 | +0.35 | +13.5% | $2.59 | $2.96 | $2.54 | 4,407,190 | |
| $2.60 | +0.20 | +8.3% | $2.41 | $2.61 | $2.371 | 3,078,317 | |
| $2.40 | 0.00 | 0.0% | $2.39 | $2.445 | $2.36 | 1,350,754 | |
| $2.40 | -0.09 | -3.6% | $2.44 | $2.45 | $2.30 | 1,313,712 | |
| $2.49 | -0.02 | -0.8% | $2.47 | $2.58 | $2.45 | 1,066,486 | |
| $2.51 | -0.07 | -2.7% | $2.59 | $2.60 | $2.50 | 1,139,426 | |
| $2.58 | +0.16 | +6.6% | $2.40 | $2.665 | $2.35 | 2,266,488 | |
| $2.42 | +0.07 | +3.0% | $2.38 | $2.43 | $2.27 | 2,010,947 | |
| $2.35 | -0.09 | -3.7% | $2.44 | $2.47 | $2.33 | 1,551,300 | |
| $2.44 | +0.17 | +7.5% | $2.26 | $2.465 | $2.25 | 1,858,600 | |
| $2.27 | -0.175 | -7.2% | $2.44 | $2.475 | $2.245 | 2,827,200 | |
| $2.445 | -0.305 | -11.1% | $2.73 | $2.73 | $2.44 | 2,449,700 | |
| $2.75 | -0.15 | -5.2% | $2.90 | $2.91 | $2.73 | 1,296,400 | |
| $2.90 | +0.06 | +2.1% | $2.85 | $2.97 | $2.71 | 3,087,100 | |
| $2.84 | +0.09 | +3.3% | $2.79 | $2.945 | $2.69 | 6,067,000 | |
| $2.75 | +0.02 | +0.7% | $2.71 | $2.845 | $2.659 | 2,264,700 | |
| $2.73 | -0.06 | -2.2% | $2.85 | $2.895 | $2.715 | 2,967,500 | |
| $2.79 | +0.17 | +6.5% | $2.62 | $2.81 | $2.555 | 3,012,000 | |
| $2.62 | +0.10 | +4.0% | $2.57 | $2.63 | $2.51 | 2,162,800 | |
| $2.52 | -0.05 | -1.9% | $2.61 | $2.62 | $2.52 | 1,544,200 | |
| $2.57 | -0.02 | -0.8% | $2.61 | $2.72 | $2.55 | 1,624,500 | |
| $2.59 | +0.08 | +3.2% | $2.54 | $2.62 | $2.51 | 1,568,500 | |
| $2.51 | -0.07 | -2.7% | $2.55 | $2.55 | $2.42 | 2,203,200 | |
| $2.58 | -0.17 | -6.2% | $2.76 | $2.78 | $2.57 | 3,117,600 | |
| $2.75 | +0.06 | +2.2% | $2.66 | $2.76 | $2.545 | 2,589,800 | |
| $2.69 | -0.23 | -7.9% | $3.12 | $3.14 | $2.67 | 5,161,700 | |
| $2.92 | +0.09 | +3.2% | $2.86 | $2.93 | $2.805 | 2,293,900 | |
| $2.83 | +0.13 | +4.8% | $2.76 | $2.89 | $2.695 | 2,489,000 | |
| $2.70 | -0.02 | -0.7% | $2.73 | $2.825 | $2.68 | 17,028,800 | |
| $2.72 | +0.01 | +0.4% | $2.80 | $2.945 | $2.71 | 3,512,900 | |
| $2.71 | +0.08 | +3.0% | $2.65 | $2.73 | $2.63 | 2,493,500 | |
| $2.63 | -0.11 | -4.0% | $2.70 | $2.71 | $2.59 | 1,680,500 | |
| $2.74 | +0.04 | +1.5% | $2.72 | $2.815 | $2.66 | 1,687,100 | |
| $2.70 | +0.05 | +1.9% | $2.68 | $2.72 | $2.62 | 2,463,600 | |
| $2.65 | -0.12 | -4.3% | $2.77 | $2.77 | $2.62 | 2,543,400 | |
| $2.77 | -0.26 | -8.6% | $3.06 | $3.06 | $2.77 | 2,963,000 | |
| $3.03 | -0.20 | -6.2% | $3.20 | $3.215 | $3.01 | 2,275,700 | |
| $3.23 | +0.15 | +4.9% | $3.04 | $3.23 | $3.04 | 1,390,400 | |
| $3.08 | 0.00 | 0.0% | $3.09 | $3.13 | $3.00 | 1,378,100 | |
| $3.08 | +0.01 | +0.3% | $3.09 | $3.23 | $2.98 | 1,678,500 | |
| $3.07 | +0.01 | +0.3% | $3.00 | $3.155 | $2.98 | 1,225,200 | |
| $3.06 | -0.10 | -3.2% | $3.12 | $3.14 | $3.025 | 2,075,700 | |
| $3.16 | -0.14 | -4.2% | $3.25 | $3.41 | $3.15 | 3,270,100 | |
| $3.30 | +0.12 | +3.8% | $3.17 | $3.37 | $3.15 | 2,665,000 | |
| $3.18 | -0.10 | -3.0% | $3.40 | $3.515 | $3.16 | 2,944,000 | |
| $3.28 | +0.28 | +9.3% | $3.05 | $3.33 | $3.05 | 4,212,991 | |
| $3.00 | -0.11 | -3.5% | $3.14 | $3.18 | $2.97 | 2,062,340 | |
| $3.11 | +0.17 | +5.8% | $2.98 | $3.245 | $2.95 | 2,109,000 | |
| $2.94 | -0.31 | -9.5% | $3.17 | $3.229 | $2.92 | 4,262,300 |
- Ticker
- BX Swiss:8EM
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BX Swiss
- Currency
- CHF
What changed lately
Latest news release · Nov 9, 2026
Editas Medicine Announces Third Quarter 2026 Results and Business Updates
Latest deck · November 2026
American Heart Association Scientific Sessions 2026
Conference · 15 slides
Latest news
Editas Medicine Announces Third Quarter 2026 Results and Business Updates
Nov 9, 2026
Closed $2.75 (+7.0%) on Nov 9, 2026
Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference
Oct 14, 2026
Closed $2.27 (-7.2%) on Oct 14, 2026
Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia
Oct 8, 2026
Closed $2.84 (+3.3%) on Oct 8, 2026
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
Sep 8, 2026
Closed $3.03 (-6.2%) on Sep 8, 2026
Editas Medicine Announces Second Quarter 2026 Results and Business Updates
Aug 5, 2026
Closed $2.90 (+5.5%) on Aug 6, 2026
Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.
Aug 4, 2026
Closed $2.75 (-0.7%) on Aug 5, 2026
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
May 28, 2026
Closed $3.46 (+0.9%) on May 29, 2026
Editas Medicine Announces Proposed Public Offering
May 26, 2026
Closed $3.08 (+11.6%) on May 26, 2026
Editas Medicine, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 14 in the last 12 months · 188 in all · newest Nov 9, 2026 · oldest 2019
- Calls
- 16 calls with a replay · 16 with a transcript · latest Aug 7, 2024
- Decks
- 26 decks · latest November 2026
Where Editas Medicine, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:EDIT · Home listing | NASDAQ | United States | USD |
| gettex:8EM | gettex | Germany | EUR |
| BOATS:EDIT | BOATS | United States | USD |
| Tradegate:8EM | Tradegate | Germany | EUR |
| LS Exchange:A2AC4K | LS Exchange | Germany | EUR |
| Stuttgart:8EM | Stuttgart | Germany | EUR |
| Lang & Schwarz:A2AC4K | Lang & Schwarz | Germany | EUR |
| LSE:0IFK | LSE | United Kingdom | USD |
| Frankfurt:8EM | Frankfurt | Germany | EUR |
| BX Swiss:8EM · This page | BX Swiss | Switzerland | CHF |
| Dusseldorf:8EM | Dusseldorf | Germany | EUR |
| Hamburg:8EM | Hamburg | Germany | EUR |
| Munich:8EM | Munich | Germany | EUR |
Valuation
EV/sales 2.4× against a median of 4.6×: 2nd lowest of 5 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $119.7M USD
- P/E
- Loss
- EV/sales
- 2.4×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 3.0×
- Gross margin
- 99.0%
- Operating margin
- −151.7%
- Net margin
- −144.9%
- Debt to equity
- 0.7×
- Beta vs S&P 500
- 2.22
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Editas Medicine, Inc. · NASDAQ:EDIT | US$253.1M | US$119.7M | n/a | 2.4× | n/a | 3.0× | −144.9% | 0.7× | 2.22 |
| Altimmune, Inc. · NASDAQ:ALT | US$258.8M | US$28.73M | n/a | n/a | n/a | 0.6× | n/a | 0.1× | 1.55 |
| Prelude Therapeutics Incorporated · NASDAQ:PRLD | US$258.6M | US$136.2M | n/a | 6.3× | n/a | 2.1× | −247.1% | 0.1× | 1.48 |
| OBI Pharma, Inc. · TPEX:4174 | US$258.4M | US$243.3M | n/a | 154× | n/a | 5.7× | n/a | 0.0× | n/a |
| TransThera Sciences (Nanjing). Inc. · HKEX:2617 | US$257.1M | US$119.1M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | n/a |
| Eikon Therapeutics, Inc. · NASDAQ:EIKN | US$256.8M | US$44.67M | n/a | n/a | n/a | 0.7× | n/a | 0.7× | 1.91 |
| SAB Biotherapeutics, Inc. · NASDAQ:SABS | US$255.7M | US$156.5M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.19 |
| Evommune, Inc. · NYSE:EVMN | US$255.5M | US$86.86M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | 0.96 |
| Q32 Bio Inc. · NASDAQ:QTTB | US$249.6M | −US$35.66M | 7.7× | −0.7× | −1.9× | 0.9× | 59.8% | 0.0× | 0.59 |
| Turn Therapeutics Inc. · NASDAQ:TTRX | US$247.5M | US$244.2M | n/a | n/a | n/a | 43.5× | n/a | 1.1× | 1.54 |
| Mabpharm Limited · HKEX:2181 | US$247.3M | US$279.5M | 29.6× | 3.0× | 28.9× | 8.5× | 8.8% | 1.6× | n/a |
| Median of the others | US$256.3M | US$127.6M | 18.7× | 4.6× | 13.5× | 1.6× | 8.8% | 0.1× | 1.48 |
Forecasts
9 strong buy · 2 hold · 2 sell · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 6.67 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.81 · 5 analysts
- Revenue, year to Dec 2026
- 29.94M · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Gilmore O’Neill | President and Chief Executive Officer |
| Amy Parison | Senior Vice President and Chief Financial Officer |
| Damien Grierson | Senior Vice President and General Counsel |
| Brieana Buckley | Senior Vice President, Development and Program Leadership |
| Dan Ory | Executive Vice President and Chief Medical Officer |
| Frank Panaccio | Senior Vice President and Chief Business Officer |
| Gregory Whitehead | Executive Vice President and Chief Technical and Quality Officer |
| Linda C. Burkly | Executive Vice President and Chief Scientific Officer |
| Tom Love | Vice President, People |
Board
| Director | Role |
|---|---|
| Jessica Hopfield | Chair |
| Andrew Hirsch | Board Member |
| Bernadette Connaughton | Board Member |
| David Scadden | |
| Gilmore O’Neill | President and Chief Executive Officer |
| Patrick T. Ellinor | Board Member |
Events
- Next results
- Mar 8, 2027 (expected)
Calls
| Call | When | Status |
|---|---|---|
| Editas Medicine (NASDAQ:EDIT) Q2 2024 Earnings Call | Wed, Aug 07, 2024 · 8:00 AM ET | Replay |
| Editas Medicine (NASDAQ:EDIT) Q1 2024 Earnings Call | Wed, May 08, 2024 · 8:00 AM ET | Replay |
| Editas Medicine (NASDAQ:EDIT) Q4 2023 Earnings Call | Wed, Feb 28, 2024 · 8:00 AM ET | Replay |
| Editas Medicine (NASDAQ:EDIT) Q3 2023 Earnings Call | Tue, Nov 28, 2023 · 8:00 AM ET | Replay |
| Editas Medicine (NASDAQ:EDIT) Q2 2023 Earnings Call | Wed, Aug 02, 2023 · 8:00 AM ET | Replay |
| Editas Medicine (NASDAQ:EDIT) Q1 2023 Earnings Call | Fri, May 05, 2023 · 8:00 AM ET | Replay |
| Editas Medicine (NASDAQ:EDIT) Q4 2022 Earnings Call | Wed, Feb 22, 2023 · 8:00 AM ET | Replay |
| Editas Medicine (NASDAQ:EDIT) Q3 2022 Earnings Call | Wed, Nov 02, 2022 · 8:00 AM ET | Replay |
| Editas Medicine (NASDAQ:EDIT) Q2 2022 Earnings Call | Wed, Aug 03, 2022 · 8:00 AM ET | Replay |
| Editas Medicine (NASDAQ:EDIT) Q1 2022 Earnings Call | Wed, May 04, 2022 · 8:00 AM ET | Replay |
All 16 calls
| Call | When | Status |
|---|---|---|
| Editas Medicine (NASDAQ:EDIT) Q4 2021 Earnings Call | Thu, Feb 24, 2022 · 8:00 AM ET | Replay |
| Editas Medicine (NASDAQ:EDIT) Q3 2021 Earnings Call | Mon, Nov 08, 2021 · 8:00 AM ET | Replay |
| Editas Medicine (NASDAQ:EDIT) Q2 2021 Earnings Call | Wed, Aug 04, 2021 · 8:00 AM ET | Replay |
| Editas Medicine (NASDAQ:EDIT) Q1 2021 Earnings Call | Wed, May 05, 2021 · 8:00 AM ET | Replay |
| Editas Medicine (NASDAQ:EDIT) Q4 2020 Earnings Call | Thu, Feb 25, 2021 · 8:00 AM ET | Replay |
| Editas Medicine (NASDAQ:EDIT) Q3 2020 Earnings Call | Thu, Nov 05, 2020 · 5:00 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 9, 2026 · Before open | +7.0% |
| Q2 2026 | Aug 5, 2026 · After close | +5.5% |
| Q1 2026 | May 5, 2026 · Before open | +1.3% |
| Q4 2025 | Feb 19, 2026 | +4.1% |
| Q3 2025 | Nov 10, 2025 · Before open | +2.0% |
| Q2 2025 | Aug 12, 2025 · After close | +34.5% |
| Q1 2025 | May 12, 2025 · After close | −2.6% |
| Q4 2024 | Feb 26, 2025 · Before open | −1.1% |
| Q3 2024 | Nov 4, 2024 · Before open | −1.0% |
| Q2 2024 | Aug 7, 2024 · Before open | −12.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · Before open | −11.4% |
| Q4 2023 | Feb 28, 2024 · Before open | +24.9% |
| Q3 2023 | Nov 3, 2023 · Before open | +18.2% |
| Q2 2023 | Aug 2, 2023 · Before open | +5.7% |
| Q1 2023 | May 5, 2023 · Before open | +12.0% |
| Q4 2022 | Feb 22, 2023 · Before open | +6.2% |
| Q3 2022 | Nov 2, 2022 · Before open | +1.1% |
| Q2 2022 | Aug 3, 2022 · Before open | +13.4% |
| Q1 2022 | May 4, 2022 · Before open | +11.5% |
| Q4 2021 | Feb 24, 2022 · Before open | +10.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| American Heart Association Scientific Sessions 2026 | Conference | 15 slides | November 2026 |
| Investor Presentation (June 2026) | Investor deck | 17 slides | June 2026 |
| TIDES 2026 | Conference | 20 slides | May 14, 2026 |
| ASGCT 29th Annual Meeting 2026 | Conference | 20 slides | May 2026 |
| ASGCT 28th Annual Meeting 2025 | Conference | 8 slides | May 2025 |
| Investor Presentation (February 2025) | Investor deck | 20 slides | February 2025 |
| 2025 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR | Conference | 18 slides | February 2025 |
| EHA2024 Hybrid Congress (June 2024) | Conference | 13 slides | Jun 15, 2024 |
| Technical Presentation (May 2024) | Technical | 13 slides | May 10, 2024 |
| Technical Presentation (December 2023) | Technical | 20 slides | Dec 11, 2023 |
All 26 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (June 2023) | Technical | 26 slides | Jun 12, 2023 |
| EHA 2023 Hybrid Congress | Conference | 13 slides | Jun 10, 2023 |
| Technical Presentation (December 2022) | Technical | 25 slides | December 2022 |
| Technical Presentation (November 2022) | Technical | 15 slides | Nov 2, 2022 |
| Technical Presentation (May 2022) | Technical | 15 slides | May 19, 2022 |
| Technical Presentation (May 2022) | Technical | 15 slides | May 16, 2022 |
| TIDES 2022 | Conference | 24 slides | May 2022 |
| TIDES 2021 | Conference | 33 slides | Sep 23, 2021 |
| TIDES USA 2021 | Conference | 25 slides | Sep 23, 2021 |
| Shareholder Meeting (May 2021) | Shareholder meeting | 17 slides | May 21, 2021 |
| European Hematology Association 2020 | Conference | 13 slides | June 2020 |
| Keystone Symposia, Engineering the Genome/Emerging Cellular Therapies 2020 | Conference | 25 slides | Feb 10, 2020 |
| Technical Presentation (October 2019) | Technical | 21 slides | October 2019 |
| Investor Presentation (May 2019) | Investor deck | 30 slides | May 9, 2019 |
| Technical Presentation (2017) | Technical | 22 slides | 2017 |
| Technical Presentation (2017) | Technical | 13 slides | 2017 |
Financings
| Raise | Date |
|---|---|
| At-the-market programme of common stock Tranche closed: US$17.3M raised Use of proceeds: Fund operating expenses and capital expenditure requirements, extending cash runway into the third quarter of 2027 | Nov 10, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$16.00 a share on Feb 2, 2016.
- Price
- US$16.00 a share
- Shares offered
- 5,900,000 shares of common stock
- Offering size
- US$94.4 million
- Underwriters' option
- Up to 885,000 more shares
- Listing
- EDIT on the Nasdaq Global Select Market
- Underwriters
- Morgan Stanley, J.P. Morgan, Cowen and Company, JMP Securities · In the order on the cover
- Shares delivered
- On or about Feb 8, 2016
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Oct 16, 2015 |
| Filed publicly | Jan 4, 2016 |
| Amended once | Jan 25, 2016 |
| Shares registered with an exchange | Jan 29, 2016 |
| Declared effective by the SEC | Feb 2, 2016 |
| Final prospectus, with the price | Feb 3, 2016 |
Filings
| Filing | Filed |
|---|---|
| 424B1 · Prospectus | Feb 3, 2016 |
| CERTNAS · Nasdaq's certificate of listing | Feb 2, 2016 |
| EFFECT · Notice that a registration is effective | Feb 2, 2016 |
| 8-A12B · Registration of shares for listing on an exchange | Jan 29, 2016 |
| CORRESP · Letter to the SEC | Jan 29, 2016 |
| CORRESP · Letter to the SEC | Jan 29, 2016 |
| S-1/A · Registration statement, amended | Jan 25, 2016 |
| CORRESP · Letter to the SEC | Jan 5, 2016 |
| S-1 · Registration statement | Jan 4, 2016 |
| DRS/A · Draft registration statement, amended | Dec 15, 2015 |
All 16 filings
| Filing | Filed |
|---|---|
| DRSLTR · Letter to the SEC with a draft | Dec 14, 2015 |
| UPLOAD · Letter from the SEC | Dec 7, 2015 |
| DRSLTR · Letter to the SEC with a draft | Nov 20, 2015 |
| DRS/A · Draft registration statement, amended | Nov 20, 2015 |
| UPLOAD · Letter from the SEC | Nov 16, 2015 |
| DRS · Draft registration statement | Oct 16, 2015 |
Open IPO · From the cover of the final prospectus (424B1) filed Feb 3, 2016
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 40.5M | 32.3M | 78.1M | 19.7M | 25.5M | 90.7M | 20.5M | 31.9M | 13.7M | 6.05M |
| Cost of revenue | 5.28M | 199.2M | 6.06M | 6.34M | 5.05M | 158.0M | 96.9M | 90.7M | 83.2M | 57.0M |
| Gross profit | 40.5M | -166.9M | 72.1M | 19.7M | 25.5M | 90.7M | -76.4M | -58.7M | -69.4M | -50.9M |
| Research and development | 90.0M | 199.2M | 177.7M | 175.0M | 142.5M | 158.0M | 96.9M | 90.7M | 83.2M | 57.0M |
| Selling, general and administrative | 49.9M | 72.0M | 69.7M | 70.7M | 76.2M | 67.6M | 64.6M | 55.0M | 50.5M | 46.3M |
| Operating income | -160.0M | -251.2M | -169.2M | -225.9M | -193.1M | -134.8M | -140.9M | -113.7M | -119.9M | -97.2M |
| Depreciation and amortization | 5.28M | 5.81M | 6.06M | 6.34M | 5.05M | 3.96M | 2.83M | 3.25M | 2.68M | 1.20M |
| EBITDA | -154.7M | -245.3M | -163.1M | -219.6M | -188.1M | -130.9M | -138.1M | -110.5M | -117.3M | -96.0M |
| Interest expense | 2.13M | 0 | 4.22M | 5.70M | 2.60M | 7.31M | 3.44M | 978.0K | 62.0K | |
| Income before tax | -160.1M | -237.1M | -153.2M | -220.4M | -192.5M | -116.0M | -133.7M | -110.0M | -120.3M | -97.2M |
| Income tax | 0 | 0 | 0 | 0 | 0 | -6.56M | -10.3M | -3.12M | -1.12M | -1.32M |
| Net income | -160.1M | -237.1M | -153.2M | -220.4M | -192.5M | -116.0M | -133.7M | -110.0M | -120.3M | -97.2M |
| Earnings per share, basic | -1.80 | -2.88 | -2.02 | -3.21 | -2.85 | -1.98 | -2.68 | -2.33 | -2.98 | -3.02 |
| Earnings per share, diluted | -1.80 | -2.88 | -2.02 | -3.21 | -2.85 | -1.98 | -2.68 | -2.33 | -2.98 | -3.02 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 146.6M | 131.5M | 123.7M | 141.5M | 203.5M | 139.7M | 238.2M | 134.8M | 146.6M | 185.3M |
| Short-term investments | 0 | 138.4M | 199.5M | 202.8M | 296.3M | 262.4M | 219.0M | 234.2M | 182.5M | 0 |
| Receivables | 15.2M | 16.3M | 10.2M | 5.14M | 267.0K | 6.05M | 418.0K | 30.0K | 679.0K | 88.0K |
| Inventory | -93.1M | -120.1M | -109.7M | 2.92M | 1.86M | 1.66M | ||||
| Current assets | 163.9M | 289.3M | 340.8M | 356.8M | 507.3M | 419.1M | 463.8M | 374.8M | 332.2M | 187.2M |
| Property, plant and equipment | 3.54M | 14.5M | 12.0M | 15.6M | 17.1M | 14.0M | 10.9M | 40.2M | 39.4M | 40.4M |
| Goodwill | 0 | 0 | ||||||||
| Total assets | 186.5M | 341.6M | 499.2M | 514.3M | 677.5M | 572.6M | 508.9M | 420.4M | 373.3M | 229.2M |
| Accounts payable | 2.60M | 5.49M | 8.27M | 9.51M | 5.05M | 6.41M | 5.84M | 5.33M | 4.02M | 4.64M |
| Current liabilities | 46.2M | 77.2M | 63.2M | 60.1M | 46.9M | 58.2M | 60.0M | 35.9M | 36.7M | 33.1M |
| Long-term debt | 53.6M | 52.4M | 0 | 33.4M | 35.1M | |||||
| Total debt | 58.6M | 57.4M | 0 | 43.9M | 26.4M | 26.1M | 29.1M | 45.2M | 40.9M | 45.1M |
| Total liabilities | 159.2M | 207.3M | 150.1M | 153.6M | 123.8M | 179.0M | 246.4M | 184.2M | 165.2M | 94.6M |
| Shareholders' equity | 27.3M | 134.3M | 349.1M | 360.7M | 553.6M | 393.6M | 262.4M | 236.2M | 208.1M | 134.6M |
| Shares outstanding | 97.9M | 82.7M | 81.8M | 68.8M | 68.4M | 62.6M | 54.4M | 48.8M | 44.5M | 35.8M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -165.2M | -210.3M | -132.2M | -177.3M | -163.8M | -179.8M | -40.7M | -45.7M | -9.42M | -50.2M |
| Capital spending | -607.0K | -8.83M | -4.72M | -4.12M | -7.98M | -7.16M | -6.17M | -4.75M | -2.06M | -3.49M |
| Free cash flow | -165.8M | -219.1M | -136.9M | -181.5M | -171.8M | -187.0M | -46.8M | -50.5M | -11.5M | -53.7M |
| Cash from investing | 138.7M | 162.1M | -3.73M | 114.1M | -54.5M | -140.5M | 12.3M | -53.1M | -183.8M | -3.47M |
| Cash from financing | 40.5M | 56.0M | 118.0M | 1.28M | 282.1M | 224.1M | 131.8M | 86.9M | 154.5M | 97.2M |
| Dividends paid | -4.00K | -11.0K | -782.0K | |||||||
| Share buybacks | 1.28M | 282.1M | 224.1M | 131.8M | 4.00K | 11.0K | 11.0K | |||
| Change in cash | 13.9M | 7.89M | -17.9M | -62.0M | 63.8M | -96.2M | 103.4M | -11.9M | -38.7M | 43.4M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 9, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2026 | Results | SEC |
| 4 · Change in ownership | Nov 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 6, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 8, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 9, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| S-8 · Registration statement for employee plans | Sep 9, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| S-3 · Registration statement | Aug 31, 2026 | Offer document | SEC |
| 144 · Notice of proposed sale | Aug 31, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 31, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 29, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 29, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jul 21, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 18, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 3, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 3, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 2, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | May 29, 2026 | Other filings | SEC |
| 424B5 · Prospectus | May 26, 2026 | Offer document | SEC |
| 8-K · Current report | May 26, 2026 | Material contract | SEC |
| S-3MEF | May 26, 2026 | Other filings | SEC |
| 8-K · Current report | May 26, 2026 | Current report | SEC |
| 424B5 · Prospectus | May 26, 2026 | Offer document | SEC |
| 8-K · Current report | May 26, 2026 | Current report | SEC |
| 8-K · Current report | May 14, 2026 | Current report | SEC |
| 10-Q · Quarterly report | May 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 28, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 7, 2026 | Current report | SEC |
| 8-K · Current report | Mar 27, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 10-K · Annual report | Mar 9, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 9, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 27, 2026 | Other filings | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 1, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 10, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2025 | Results | SEC |
| 8-K · Current report | Oct 9, 2025 | Current report | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 2, 2025 | Current report | SEC |
| 144 · Notice of proposed sale | Aug 29, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 29, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 30, 2025 | Other filings | SEC |
| 8-K · Current report | Jun 12, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 2, 2025 | Other filings | SEC |
| 8-K · Current report | Jun 2, 2025 | Management or board change | SEC |
| 8-K · Current report | May 14, 2025 | Current report | SEC |
| 8-K · Current report | May 13, 2025 | Current report | SEC |
| 10-Q · Quarterly report | May 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 17, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 15, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 15, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 15, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 8, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 8, 2025 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Apr 4, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Mar 24, 2025 | Other filings | SEC |
| 8-K · Current report | Mar 20, 2025 | Management or board change | SEC |
| POS AM · Amendment to an effective registration | Mar 5, 2025 | Offer document | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 5, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 5, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 5, 2025 | Results | SEC |
| POSASR | Mar 5, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 28, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 28, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 28, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 13, 2025 | Results | SEC |
| 8-K · Current report | Dec 17, 2024 | Management or board change | SEC |
| 8-K · Current report | Dec 12, 2024 | Management or board change | SEC |
| 8-K · Current report | Dec 9, 2024 | Current report | SEC |
| 4 · Change in ownership | Dec 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 5, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 4, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2024 | Results | SEC |
| 8-K · Current report | Oct 22, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 17, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 3, 2024 | Material contract | SEC |
| 4 · Change in ownership | Sep 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 6, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 29, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 29, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2024 | Results | SEC |
| 4 · Change in ownership | Jul 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 22, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 18, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 18, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Jul 10, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jun 27, 2024 | Management or board change | SEC |
| 8-K · Current report | Jun 14, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 31, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | May 31, 2024 | Other filings | SEC |
| 8-K · Current report | May 31, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | May 22, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 17, 2024 | Other filings | SEC |
| 4 · Change in ownership | May 14, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2024 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 16, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 16, 2024 | Meeting notice | SEC |
| SC 13G/A · Big-stake notice, amended | Apr 10, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 4, 2024 | Other filings | SEC |
| S-3ASR · Registration statement | Feb 28, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Feb 28, 2024 | Offer document | SEC |
| 10-K · Annual report | Feb 28, 2024 | Annual report | SEC |
| 8-K · Current report | Feb 28, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 24, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 10, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Dec 13, 2023 | Current report | SEC |
| 8-K · Current report | Dec 11, 2023 | Current report | SEC |
| 4 · Change in ownership | Dec 7, 2023 | Insider trade | SEC |
| 8-K · Current report | Nov 22, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Nov 16, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 9, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 3, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 3, 2023 | Results | SEC |
| 8-K · Current report | Oct 10, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Sep 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 10, 2023 | Insider trade | SEC |
| SC 13G · Big-stake notice | Aug 4, 2023 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 2, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 2, 2023 | Results | SEC |
| 4 · Change in ownership | Jul 25, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 25, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 21, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 15, 2023 | Material contract | SEC |
This page holds 200 of 733 filings. Open Filings
Cap table
Built by 6ix from Editas Medicine, Inc.’s releases · as of Nov 6, 2026
- Common shares
- 154,339,748
- Fully diluted
- 154,339,748
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 154,339,748 | Nov 6, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 6, 2026 | 154,339,748 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Alexis Borisy Other companies: Parabilis Medicines, Inc. (Lead Independent Director; Chairman, Nextech Invest; Chairman, Curie.Bio · Since at least Jun 9, 2026); Tango Therapeutics, Inc. (Director · Since at least Aug 10, 2021); Relay Therapeutics, Inc. (Director · Since at least Jul 15, 2020); Revolution Medicines, Inc. (Director · Since at least Feb 12, 2020); Blueprint Medicines Corp (Director · Since at least Apr 30, 2015); OPKO Health, Inc. (Director · May 9, 2022 – Jun 22, 2023 · Past); EQRx Inc (Executive Chairman, Director · Dec 17, 2021 – Nov 9, 2023 · Past); Dianthus Therapeutics, Inc. (Director · Jun 20, 2018 – Aug 26, 2021 · Past); Foundation Medicine Inc (Director · Sep 24, 2013 – Jul 31, 2018 · Past); EPIRUS Biopharmaceuticals Inc (CEO & President, Director · Jan 26, 2006 – Jan 26, 2009 · Past) | Director · Feb 2, 2016 – Jun 15, 2017 · Past |
| Douglas G Cole Other companies: Foghorn Therapeutics Inc. (Director · Since at least Oct 22, 2020); Sana Biotechnology, Inc. (Director · Feb 3, 2021 – Jun 6, 2024 · Past); Sigilon Therapeutics Inc (Director · Dec 3, 2020 – Aug 11, 2023 · Past); Denali Therapeutics Inc. (Director · Dec 7, 2017 – Jun 1, 2023 · Past); Quanterix Corporation (Director · Dec 6, 2017 – Jan 2, 2019 · Past); Agios Pharmaceuticals, Inc. (Director · Jul 23, 2013 – Aug 10, 2016 · Past); Receptos Inc (Director · May 8, 2013 – Jul 17, 2013 · Past); Tetraphase Pharmaceuticals Inc (Director · Mar 19, 2013 – Mar 25, 2013 · Past); AVEO Pharmaceuticals Inc (Director · Mar 11, 2010 – May 12, 2011 · Past) | Director · Feb 2, 2016 – Aug 17, 2017 · Past |
| Cynthia Collins Other companies: Codexis, Inc. (Director · Since at least Mar 28, 2025); MaxCyte, Inc. (Non-Executive Director · Since at least Oct 14, 2024); Certara, Inc. (Director · Since at least Aug 1, 2020); Poseida Therapeutics Inc (Director · Jul 23, 2021 – Jan 8, 2025 · Past); Constellation Alpha Capital Corp (Director · Aug 29, 2019 – Jun 1, 2023 · Past); GenVec Inc (President & CEO, Director · May 23, 2012 – Jan 23, 2013 · Past); Beckman Coulter Inc (Group Vice President · Jul 1, 2007 – Jun 30, 2011 · Past) | CEO · Dec 6, 2018 – Feb 9, 2021 · Past |
| Andrew A F Hack Other companies: Mersana Therapeutics Inc (Director · Since at least Jun 27, 2017); Nuvalent, Inc. (Director · Jul 28, 2021 – Dec 11, 2024 · Past); Atea Pharmaceuticals, Inc. (Director · Oct 29, 2020 – Nov 3, 2020 · Past); BCLS Acquisition Corp (Chief Financial Officer, Director · Oct 21, 2020 – Oct 26, 2020 · Past); Dynavax Technologies Corporation (Director · Aug 12, 2019 – Aug 8, 2023 · Past); Allena Pharmaceuticals Inc (Director · Jun 8, 2018 – Nov 17, 2020 · Past) | Chief Financial Officer · Feb 2, 2016 – Feb 4, 2019 · Past |
| Erick J. Lucera Other companies: Dyne Therapeutics, Inc. (Chief Financial Officer · Since at least Mar 31, 2025); SAB Biotherapeutics, Inc. (Director · Since at least Apr 3, 2023); Beyond Air, Inc. (Audit Chair · Since at least Aug 10, 2017); Bone Biologics Corp (Director · Oct 15, 2021 – Sep 18, 2023 · Past); AVEO Pharmaceuticals Inc (Chief Financial Officer · Jan 6, 2020 – Jan 19, 2023 · Past); Valeritas Holdings Inc (See Remarks · Mar 22, 2017 – Mar 7, 2019 · Past) | EVP, CHIEF FINANCIAL OFFICER · May 17, 2023 – Mar 8, 2025 · Past |
| Emma Reeve Other companies: Whitehawk Therapeutics, Inc. (Director · Since at least Sep 8, 2021); PTC Therapeutics, Inc. (Director · Since at least Dec 14, 2018); Constellation Pharmaceuticals Inc (Chief Financial Officer · Jul 18, 2018 – Jul 15, 2021 · Past); PAREXEL International Corp (Corp. VP & Interim CFO · Jul 16, 2016 – Dec 7, 2016 · Past) | Director · Sep 3, 2021 – May 30, 2024 · Past |
| John Mendlein Other companies: Fate Therapeutics, Inc. (Director · Since at least Sep 30, 2013); Omega Therapeutics Inc (Director · Jul 29, 2021 – Jun 20, 2024 · Past); Moderna, Inc. (See Remarks · Dec 7, 2018 – Dec 7, 2018 · Past); aTyr Pharma, Inc. (Director · May 6, 2015 – May 8, 2019 · Past) | Director · Feb 2, 2016 – Jun 15, 2017 · Past |
| Akshay Vaishnaw Other companies: Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); Scholar Rock Holding Corporation (President of R&D · Since at least May 21, 2019); Alnylam Pharmaceuticals, Inc. (President · Mar 4, 2009 – Aug 3, 2023 · Past) | Director · Jul 28, 2016 – May 30, 2024 · Past |
| Andrew Hirsch Other companies: C4 Therapeutics, Inc. (President and Chief Executive Officer, Director · Since at least Oct 1, 2020); Agios Pharmaceuticals, Inc. (Chief Financial Officer · Sep 19, 2016 – Apr 22, 2020 · Past); BIND Therapeutics Inc (PRESIDENT & CEO, Director · Sep 19, 2013 – Jun 22, 2015 · Past) | Board Member · Since at least May 30, 2017 |
| David Scadden Other companies: Agios Pharmaceuticals, Inc. (Independent Director · Since at least May 27, 2017); Carisma Therapeutics, Inc. (Director · Jun 30, 2024 – Jul 1, 2024 · Past); Dianthus Therapeutics, Inc. (Director · Jun 20, 2018 – Jun 28, 2022 · Past) | Director · Since at least Feb 5, 2019 |
All 38 people
| Person | Seat |
|---|---|
| Gilmore O’Neill Other companies: Aptinyx Inc (Director · Oct 19, 2021 – May 26, 2022 · Past); Unity Biotechnology Inc (Director · Dec 10, 2020 – Jun 21, 2024 · Past); Sarepta Therapeutics, Inc. (EVP, R&D & CMO · Jun 7, 2018 – Mar 3, 2021 · Past) | President and Chief Executive Officer · Since at least Jun 1, 2022 |
| Michelle Robertson Other companies: Geron Corporation (Executive Vice President, Chief Financial Officer and Treasurer · Since at least Sep 25, 2023); Verastem, Inc. (Member, Audit Committee; Member, Compensation Committee · Since at least Nov 15, 2021); Momenta Pharmaceuticals Inc (Chief Financial Officer · Oct 5, 2018 – Oct 25, 2019 · Past) | EVP, CHIEF FINANCIAL OFFICER · Jan 9, 2020 – May 11, 2023 · Past |
| Bernadette Connaughton Other companies: Halozyme Therapeutics, Inc. (Director · Since at least Sep 7, 2018); Syneos Health Inc (Director · Nov 12, 2019 – Sep 28, 2023 · Past) | Board Member · Since at least Oct 26, 2021 |
| Elliott Levy Other companies: NuCana plc (Non Executive Director · Since at least Mar 18, 2026); Omega Therapeutics Inc (Director · Jul 29, 2021 – Jun 20, 2024 · Past) | Director · Since at least Apr 11, 2023 |
| Jessica Hopfield Other companies: Maravai LifeSciences Holdings, Inc. (Director · Since at least May 23, 2024); Insulet Corporation (Director · Since at least May 22, 2024) | Chair · Since at least May 13, 2024 |
| Kevin Bitterman Other companies: Disc Medicine, Inc. (Director · Since at least Dec 29, 2022); Akero Therapeutics Inc (Director · Jun 19, 2019 – Jun 1, 2021 · Past) | Director · Feb 2, 2016 – Jun 15, 2017 · Past |
| James C Mullen Other companies: Thermo Fisher Scientific Inc (Director · May 18, 2022 – May 21, 2025 · Past) | CEO, Director · Apr 14, 2022 – Apr 14, 2022 · Past |
| Judith R Abrams Other companies: CorMedix Inc. (Chief Medical Officer · Feb 1, 2017 – Feb 1, 2017 · Past) | Chief Medical Officer · Oct 28, 2019 – Oct 28, 2019 · Past |
| Meeta Chatterjee Other companies: Werewolf Therapeutics, Inc. (Board member · Since at least Oct 28, 2021) | Director · Dec 17, 2020 – May 30, 2024 · Past |
| Amy Parison | Senior Vice President and Chief Financial Officer · Since at least May 12, 2025 |
| Baisong Mei | EVP, CHIEF MEDICAL OFFICER · Jul 18, 2022 – Dec 3, 2024 · Past |
| Boris Nikolic | Director · Feb 2, 2016 – Jun 15, 2018 · Past |
| Brieana Buckley | Senior Vice President, Development and Program Leadership · Since at least Nov 4, 2026 |
| Bruce Eaton | EVP, CBO AND CTO · Jul 23, 2021 – Dec 5, 2023 · Past |
| Charles Albright | EVP/Chief Scientific Officer · Aug 22, 2016 – Dec 15, 2020 · Past |
| Damien Grierson | Senior Vice President and General Counsel · Since at least Nov 5, 2026 |
| Daniel Scott Ory | EVP, Chief Medical Officer · Since at least Sep 8, 2026 |
| Dan Ory | Executive Vice President and Chief Medical Officer · Since at least Oct 8, 2026 |
| Frank Panaccio | Senior Vice President and Chief Business Officer · Since at least Nov 4, 2026 |
| Gregory Whitehead | Executive Vice President and Chief Technical and Quality Officer · Since at least Nov 5, 2026 |
| Katrine Bosley | President and CEO, Director · Feb 2, 2016 – Jan 8, 2019 · Past |
| Linda C. Burkly | Executive Vice President and Chief Scientific Officer · Since at least Jul 24, 2023 |
| Lisa Anne Michaels | EVP/Chief Medical Officer · Nov 9, 2020 – Dec 22, 2021 · Past |
| Mark S Shearman | EVP, CHIEF SCIENTIFIC OFFICER · Jun 14, 2021 – Feb 13, 2023 · Past |
| Patrick T. Ellinor | Board Member · Since at least Aug 5, 2026 |
| Patrick Thomas Ellinor II | Director · Since at least Aug 6, 2026 |
| Tom Love | Vice President, People · Since at least Nov 4, 2026 |
| Vickesh Myer | Chief Technology Officer · Jun 15, 2018 – Mar 18, 2019 · Past |
Log in to ask 6ix AI your own questions about Editas Medicine, Inc.